Cullinan Oncology, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1/A
Total revenues [+]	0.0	18.9	0.0	16.8	9.6
Royalties				16.8	9.6
Revenue growth	-100.0%		-100.0%	75.2%
Cost of goods sold	0.0	0.0	0.0	22.3	14.6
Gross profit	0.0	18.9	0.0	-5.5	-5.0
Gross margin		100.0%		-32.7%	-52.2%
Selling, general and administrative [+]	132.1	86.9	60.3	5.5	5.0
General and administrative				5.5	5.0
Other operating expenses			-6.4	11.3	4.6
EBITDA [+]	-132.0	-67.9	-53.8	-22.2	-14.5
EBITDA growth	94.6%	26.1%	142.5%	52.7%
EBITDA margin		-358.2%		-132.2%	-151.7%
Depreciation and amortization	0.1	0.1	0.1	0.1	0.0
EBIT [+]	-132.1	-68.0	-53.9	-22.3	-14.6
EBIT growth	94.5%	26.1%	142.0%	52.7%
EBIT margin		-358.7%		-132.7%	-152.2%
Non-recurring items			6.4
Interest income	6.6	0.5	0.9		0.4
Interest income	6.6	0.5	0.9		0.4
Other income (expense), net [+]	276.8	0.0	7.6	0.6
Other				0.0
Pre-tax income	151.3	-67.5	-51.8	-21.7	-14.2
Income taxes	42.1	0.0	0.0	0.0	0.0
Tax rate	27.8%	0.0%	0.0%	0.0%	0.0%
Minority interest			7.7	-1.0
Net income	111.2	-65.6	-51.8	-21.7	-14.2
Net margin		-346.1%		-129.0%	-148.0%

Basic EPS [+]	$2.46	($1.52)	($2.60)	($21,654.00)	($14,189.00)
Growth	-261.8%	-41.6%	-100.0%	52.6%
Diluted EPS [+]	$2.38	($1.52)	($2.60)	($21,654.00)	($14,189.00)
Growth	-256.7%	-41.6%	-100.0%	52.6%

Shares outstanding (basic) [+]	45.2	43.1	19.9	0.0	0.0
Growth	4.8%	116.6%	1988630.7%	0.0%
Shares outstanding (diluted) [+]	46.6	43.1	19.9	0.0	0.0
Growth	8.3%	116.6%	1988630.7%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.